On this page
Spinal muscular atrophy (SMA) here refers to 5q SMA caused by biallelic disease-causing variants in SMN1. Loss of motor neurons produces symmetric, usually proximal weakness that can affect movement, breathing, coughing, speech, and swallowing. Age at onset and function vary, and disease-modifying treatment is changing the natural history; historical type labels alone no longer predict an individual's course.
Urgent boundaries
A positive newborn screen or newly suspected SMA needs prompt confirmatory testing and same-day contact with an experienced neuromuscular team. Early irreversible motor-neuron loss makes a wait-and-see approach unsafe, including before symptoms are apparent.
Seek urgent or emergency assessment for increased work of breathing, color change, pauses in breathing, unusual sleepiness or confusion, a weak or ineffective cough with retained secretions, or rapid decline during a respiratory infection. The person's respiratory plan and equipment should accompany them when possible; acute clinicians should know that weakness can make distress or cough appear less dramatic.
Choking, wet or gurgly breathing after intake, inability to manage secretions, markedly reduced intake, dehydration, or sudden loss of feeding ability also needs urgent review. Do not change food or liquid texture, stop oral intake, start oxygen, or alter ventilation solely from this page; these decisions require the person's medical and swallowing plan.
Quick reference
| Topic | Condition-specific guidance |
|---|---|
| Cause | Biallelic disease-causing SMN1 variants; this page does not cover every non-5q motor-neuron disorder |
| Modifier | SMN2 copy number can inform expectations and treatment decisions but does not determine an individual's outcome |
| Diagnosis | Newborn screening or clinical suspicion followed by confirmatory molecular testing |
| Treatment | Disease-modifying therapy is time-sensitive and selected through specialist shared decision-making |
| Core care | Neuromuscular, respiratory, nutrition and swallowing, rehabilitation, orthopedic, and psychosocial care based on current function |
| Communication | Motor speech and access may change while language, judgment, and self-determination remain intact |
Recognition and diagnosis
Possible presentations include hypotonia, symmetric proximal weakness, reduced reflexes, loss or non-attainment of motor skills, weak cry or cough, feeding difficulty, or later-onset gait and endurance changes. A newborn screen usually detects the common SMN1 exon 7 deletion but is not the final diagnostic result.
Confirmatory testing evaluates SMN1 copy number and, when needed, sequence variants; SMN2 copy number is also reported because it can help guide time-sensitive treatment discussions. Results should be interpreted by an SMA-experienced neuromuscular and genetics team. Carrier and reproductive counseling are separate from predicting an affected person's function.
Disease-modifying and multidisciplinary care
Current U.S. disease-modifying options include the SMN2-directed therapies nusinersen and risdiplam and two formulations of SMN1 gene-replacement therapy: onasemnogene abeparvovec-xioi (Zolgensma) and, for eligible people age 2 years and older, onasemnogene abeparvovec-brve (Itvisma). Indications, route, eligibility, risks, monitoring, access, and regulatory status differ. Treatment choice, timing, changes, or combinations belong to shared decision-making with an experienced neuromuscular team; this page does not recommend one product.
Treatment can preserve or improve function and has altered expected outcomes, especially when started before symptoms, but it does not restore motor neurons already lost or replace respiratory, nutrition, rehabilitation, orthopedic, and participation-focused care. Track outcomes that matter to the person as well as standardized motor and respiratory measures.
Historical types 0 through 4 describe onset and highest motor milestone in the untreated era. They may still help communicate history, but current function, respiratory and bulbar status, treatment exposure, comorbidities, and the person's goals are more useful for care planning.
Breathing, swallowing, and movement
Respiratory weakness can reduce cough, ventilation during sleep, and reserve during infection. An individualized plan may include surveillance, airway-clearance support, cough assistance, noninvasive ventilation, immunization, and escalation instructions, chosen and taught by the respiratory team. Review the plan before surgery, sedation, travel, or respiratory illness.
Bulbar weakness can affect chewing, swallowing, secretion management, endurance, nutrition, and the coordination of swallowing with breathing. Assessment should consider positioning, fatigue, mealtime duration, respiratory status, growth or weight, and the person's preferences. Clinical and instrumental swallowing evaluation can guide individualized strategies; tube feeding is not an automatic consequence of diagnosis and does not determine whether tastes or oral intake are safe for a particular person.
Rehabilitation should support comfort, range of motion, mobility, positioning, bone health, energy conservation, and chosen activities without assuming that walking is the only meaningful outcome. Equipment and personal assistance should expand autonomy and participation rather than substitute for the person's decisions.
Communication and AAC
5q SMA primarily affects motor function; it does not justify assumptions about cognition, language, consent capacity, or quality of life. Weak breath support, facial or jaw weakness, fatigue, ventilation interfaces, or reduced movement can make speech or device access slow while comprehension remains strong. Address the person directly and allow enough time for their response.
AAC may be temporary, part-time, or long-term and can include speech, gesture, writing, alphabet or topic boards, stored messages, text-to-speech, partner-assisted scanning, or speech-generating systems. Voice banking or message banking may be offered as a choice, not as a prediction of decline.
Feature-match access to reliable current movement, positioning, endurance, vision, hearing, literacy, environments, and preference. Touch, adapted keyboards or pointers, switches, eye tracking, and partner-assisted scanning are possibilities to test rather than diagnosis-based defaults. Include urgent messages for breathing, suction, positioning, pain, and consent; keep an accessible low-tech backup and review access as function or treatment changes. See the AAC assessment and acquisition guide and ASHA AAC Practice Portal.
Support and key sources
- GeneReviews: Spinal Muscular Atrophy, revised February 2026
- Schroth et al.: 2024 SMA diagnosis best-practice update
- Schroth et al.: 2024 SMA treatment best-practice update
- Mercuri et al.: Diagnosis, rehabilitation, orthopedic, and nutrition standards of care
- Finkel et al.: Pulmonary and acute-care standards of care
- FDA: Itvisma and FDA: Zolgensma
- Cure SMA: Community support
- ASHA: Augmentative and Alternative Communication